2 completed, 1 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
Follow deleobuvir: new trials by email Literature Review of deleobuvir trials Research Report on deleobuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients BI 201335, ribavirin, BI 207127 - Hepatitis C, Chronic | Phase 3 | Withdrawn | Boehringer Ingelheim | 2013-05-01 | 2014-01-23 | |
| IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127 - Hepatitis C, Chronic | Phase 3 | Completed | Boehringer Ingelheim | 470 | 2012-12-01 | 2016-04-18 |
| Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment - Hepatitis C, Chronic | Phase 3 | Completed | Boehringer Ingelheim | 496 | 2012-11-01 | 2016-02-12 |
Spain (3) · Australia (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Portugal (2) · United Kingdom (2) · United States (2) · Austria (1) · Belgium (1) · Greece (1) · Hungary (1) · Ireland (1) · Netherlands (1)